KaloBios Pharmaceuticals to price public offering of common stock

Funds to develop, advance product candidates and fund working capital

By Devika Patel

Knoxville, Tenn., Sept. 23 - KaloBios Pharmaceuticals, Inc. said it plans to price a public sale of its common stock with a 30-day greenshoe.

Leerink Swann LLC is the bookrunner, and William Blair & Co., LLC, Needham & Co. LLC and JMP Securities LLC are the co-managers.

The company will use the proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.

The biopharmaceutical company is based in San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.